US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Completed · Phase 4

Conditions studied: Acellular Pertussis, Tetanus, Diphtheria

In brief

New immunization recommendations in the US include vaccination of adolescents against pertussis and meningococcal disease. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed) and MCV4 (Meningococcal conjugate vaccine against serotypes A, C, Y and W-135) vaccines be administered to adolescents at the same office visit if vaccination with both vaccines is indicated. Therefore, this study is designed to evaluate the safety and immunogenicity of a booster vaccination with Boostrix co-administered with Menactra as compared to the administration of either vaccine alone in healthy adolescents 11 - 18 years of age.

Key facts

Study ID

NCT00282295

Run by

GlaxoSmithKline

People needed

1344

Starts

2006-01-25

Expected to finish

2006-08-08

Last updated by the study team

2018-08-17

Who can join

Age: 11 and older, up to 18. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as established by medical history and history-directed physical examination before entering into the study.
• Previously completed routine childhood vaccinations against diphtheria, tetanus and pertussis diseases according to the recommended vaccination schedule at the time.
• Females of childbearing potential at the time of study entry are required to have a negative pregnancy test prior to administration of the dose of vaccine and are required to be abstinent or use adequate contraceptive precautions for one month prior to vaccination. Subjects also are required to agree to continue such precautions for two months after vaccination.

You may not qualify if…

• Administration of a pre-school booster of DTP vaccine within the previous 5 years
• Administration of a diphteria-tetanus (Td) booster within the previous 5 years
• Previous vaccination against N. meningitidis
• Hypersensitivity to latex
• History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphteria toxoid or pertussis-containing vaccine or any component of the study vaccines
• History of encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) within seven days of administration of a previous dose of pertussis vaccine taht is not attributable to another identifiable cause
• Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy: pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized
• Previous history of Guillain-Barré syndrome

Where it is running

• GSK Investigational Site — Chandler, Arizona, United States
• GSK Investigational Site — Little Rock, Arkansas, United States
• GSK Investigational Site — Fountain Valley, California, United States
• GSK Investigational Site — Golden, Colorado, United States
• GSK Investigational Site — Marietta, Georgia, United States
• GSK Investigational Site — Louisville, Kentucky, United States
• GSK Investigational Site — Annapolis, Maryland, United States
• GSK Investigational Site — Frederick, Maryland, United States
• GSK Investigational Site — Omaha, Nebraska, United States
• GSK Investigational Site — Whitehouse Station, New Jersey, United States
• GSK Investigational Site — Pittsford, New York, United States
• GSK Investigational Site — Rochester, New York, United States
• GSK Investigational Site — Akron, Ohio, United States
• GSK Investigational Site — University Heights, Ohio, United States
• GSK Investigational Site — Erie, Pennsylvania, United States
• GSK Investigational Site — Erie, Pennsylvania, United States
• GSK Investigational Site — Greenville, Pennsylvania, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Pittsburgh, Pennsylvania, United States
• GSK Investigational Site — Pittsburgh, Pennsylvania, United States
• GSK Investigational Site — Temple, Texas, United States
• GSK Investigational Site — Salt Lake City, Utah, United States
• GSK Investigational Site — Salt Lake City, Utah, United States
• GSK Investigational Site — West Jordan, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.